Methylation and expression of PTPN22 in esophageal squamous cell carcinoma
Metrics: PDF 1370 views | HTML 1792 views | ?
Jiaying Deng1,2,*, Junhua Zhang1,2,*, Chunyu Wang1,2, Qing Wei3, Daizhan Zhou4, Kuaile Zhao1,2
1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
3Department of Pathology, Tenth People’s Hospital of Tongji University, Shanghai 200072, China
4Bio-X Center, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200030, China
*These authors have contributed equally to this work
Daizhan Zhou, email: [email protected]
Kuaile Zhao, email: [email protected]
Keywords: PTPN22, ESCC, methylation, expression, prognosis
Received: June 29, 2016 Accepted: August 17, 2016 Published: August 24, 2016
Esophageal squamous cell carcinoma (ESCC) is a fatal disease contributed by both genetic and epigenetic factors. The epigenetic alteration of protein tyrosine phosphatase non-receptor type 22 (PTPN22) and its clinical significance in ESCC were still not yet clarified. A quantitative methylation study of PTPN22 and its expression were conducted in 121 and 31 paired tumor and adjacent normal tissue (ANT), respectively. Moreover, the association between PTPN22 methylation and clinicopathological parameters was evaluated. We found that the methylation level of PTPN22 was significantly elevated in tumor tissues (66.3%) relative to ANT (62.1%) (p=0.005). The methylation level of non-smoking ANT (59.1%) was significant lower than smoking ESCC tissue (65.8%) (p=0.03); similarly, the methylation levels in ANT with no lymph node invasion (57.6%) were significant lower than tumor tissues with lymph node invasion (67.5%) (p=0.001). PTPN22 expression in ESCC was lower than normal tissues, however the difference was not statistically significant (p=0.55). Lower expression was more frequently occurred in N1-3 and III stage patients, while higher expression was more likely to occur in N0 and I-II stage patients. Lower expression of PTPN22 was associated with poor overall survival (p=0.04). Taken together, PTPN22 was hypermethylationed in ESCC. Hypermethylation was associated with lymph node invasion. The PTPN22 expression may act as a prognostic biomarker to identify patients at risk of high grade.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.